-
-
-
-
-
-
-
Cellular Biomedicine Group (CBMG) Enters Into Definitive Merger Agreement; Transaction Would Result In Company Going Private
-
-
-
-
-
-
-
Cellular Biomedicine Group Reports Full-Year 2017 Financial Results and Recent Operational Progress
-
-
-
-
-
-
-
Cellular Biomedicine Group (CBMG) Approved to Commence Phase I Trial (CARD-1) for C-CAR011 in Patients with Refractory Diffuse Large B-cell Lymphoma (DLBCL) in China
-
-
-
-
-
-
-
Cellular Biomedicine Group (CBMG) Issues Response to Immuno-Oncology Cell Therapy Platform Questions
-
-
-
-
-
-
-
Unusual 11 Mid-Day Movers 6/5: (YGE) (SHOS) (JASO) Higher; (ZUMZ) (LTBR) (VNCE) Lower
-
-
-
-
-
-
-
Cellular Biomedicine Group (CBMG) Acquiring Chinese PLA General Hospital's CAR-T (CD19/CD20/CD30/EGFR) Immuno-Oncology Technology and Clinical Data
-
-
-
-
-
-
1,158,060 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

